This open-label, three-arm, randomized, phase II trial was carried out in patients with advanced hormone receptor-positive, HER2-positive breast cancer, who had received at least two prior HER2-directed therapies—including trastuzumab emtansine (T-DM1)—and a taxane. Here, NR4A1 is linked to breast cancer.